On Mondays, Sangamo Therapeutics, Inc.. (NASDAQ:SGMO) regained development and commercialization rights to gyroctocogene fitelparvovec, an investigational gene therapy product candidate for moderate to severe hemophilia A that it has co-developed and licensed. Pfizer Inc. (NYSE:PFE).
Pfizer decided to terminate the global collaboration and licensing agreement between the parties. Sangamo intends to explore all options to advance the program, including seeking a potential new collaborative partner.
Also read: FDA approves second Pfizer hemophilia drug in six months
In July 2024, Pfizer announced topline results from the Phase 3 AFFINE trial of gyroctocogene fitelparvovec, which demonstrated that the trial met key primary and secondary endpoints of superiority compared to prophylaxis.
“…we believe it is well positioned for regulatory filings and potential commercialization,” said Sandy Macrae, CEO of Sangamo Therapeutics. “While we were surprised and very disappointed by Pfizer’s decision to end our collaboration so close to the anticipated BLA and MAA filings…”
The collaboration and licensing agreement with Pfizer will end effective April 21, 2025. All trial participants will continue to be monitored as planned during the transition period.
Sangamo believes that its recently announced partnerships with Roche Holdings AG (OTC: RHHBY) Genetech and Astellas Pharma Inc (OTC:ALPMF) (OTC:ALPMY) and advanced business development discussions for its Fabry gene therapy program will allow it to chart a path forward for its genomic medicine pipeline in neurology.
Company Prepares to Initiate Expected Patient Enrollment in Phase 1/2 Study of ST-503 for Idiopathic Small Fiber Neuropathy in Mid-2025 and File Early Clinical Trial Authorization Filing for Prion Disease Program in the fourth quarter of 2025, each subject to obtaining additional financing.
Price action: SGMO shares fell 54.70% to $1,106 during the pre-market session at last check on Tuesday.
Read next:
Up next: Transform your trading with Benzinga Edge’s one-of-a-kind market trading ideas and tools. Click now to access unique information that can position you ahead in today’s competitive market.
Get the latest stock analysis from Benzinga?
This article Sangamo Therapeutics Shares Plunge as Pfizer Ends Hemophilia Gene Therapy Pact originally appeared on Benzinga.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.